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Florence Schleich, MD, PhD
a Liege, BelgiumWhat is already known about this topic? Asthmatics and patients with chronic obstructive pulmonary disease (COPD)
are at risk of more severe outcomes with common cold virus infections. Prior studies have suggested that allergic dis-
eases, asthma, and COPD may not be risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)
infection.
What does this article add to our knowledge? The strength of this study is the characterization of obstructive disease
according to lung function testing. In our study, asthma, COPD, and treatment with inhaled corticosteroid (ICS) or oral
corticosteroid were not risk factors for admission to the intensive care unit or mortality.
How does this study impact current management guidelines? Our results confirm the recommendations that patients
with obstructive airway disease should not decrease the dose of ICS during SARS-CoV2 infection. Asthma and COPD
treatments should be pursued and adapted to ensure optimal control of the lung disease throughout the pandemic,
potentially reducing the risk of severe coronavirus disease 2019.BACKGROUND: Asthmatics and patients with chronic
obstructive pulmonary disease (COPD) have more severe
outcomes with viral infections than people without obstructive
disease.
OBJECTIVE: To evaluate if obstructive diseases are risk factors
for intensive care unit (ICU) stay and death due to coronavirus
disease 2019 (COVID19).
METHODS: We collected data from the electronicmedical record
from 596 adult patients hospitalized in University Hospital of
Liege between March 18 and April 17, 2020, for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV2) infection. We
classified patients into 3 groups according to the underlying
respiratory disease, present before the COVID19 pandemic.
RESULTS: Among patients requiring hospitalization for
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COVID19- Disease due to the novel coronavirus discovered in
late 2019 in Wuhan, China, later renamed SARS-
CoV2CRP- C-reactive protein
CT- Computed tomographyFEV1- Forced expiratory volume in 1 second
ICS- Inhaled corticosteroid
ICU- Intensive care unit
LDH- Lactate dehydrogenase
OCS- Oral corticosteroid
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admission and death related to SARS-CoV2 infection.  2020
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Asthmatics and patients with chronic obstructive pulmonary
disease (COPD) are at risk of more severe outcomes with com-
mon cold virus infections than are people without obstructive
lung disease.1,2 This seems to be partly due to a deficient and
delayed innate antiviral immune response in these patients.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is
a new virus that appeared in China in the end of 2019 and is
responsible for coronavirus disease 2019 (COVID19). At the
beginning of the COVID19 pandemic, respiratory physicians
were worried about the vulnerability of patients exhibiting
chronic obstructive airway disease in case of SARS-CoV2 infec-
tion. It seemed inevitable that patients with airway obstruction
were at risk of severe COVID19. In the first publications from
Wuhan in China,3 the prevalence of obstructive diseases in pa-
tients with COVID19 was surprisingly lower than that reported
in the general population. The authors concluded that allergic
diseases, asthma, and COPD were not risk factors for SARS-
CoV2 infection. However, they found that older age, high
number of comorbidities, and more prominent laboratory
abnormalities were associated with severity of disease. It was
suggested that chronic pulmonary disease was underdiagnosed in
the first studies or that there was a possible protective effect of
inhaled corticosteroids (ICS).4
Some authors hypothesize that type 2 inflammation may
suppress antiviral immunity in the lung5 and may increase
susceptibility to severe COVID19. Suppressing type 2 inflam-
mation with the use of topical steroids might thus restore local
antiviral immunity.
Moreover, it has been shown that poor asthma control was a
risk factor for greater virus-induced exacerbations severity.6 LikeH5N1 and H7N9,7 SARS-CoV2 is responsible for severe
lymphopenia. SARS-CoV2-infected patients also presented with
eosinopenia, extensive highly hypoxemic interstitial pneumonia,
in the most severe cases diffuse lung tissue damage, a cytokine
storm leading to acute respiratory distress syndrome requiring
intensive care unit (ICU) stay, and mechanical ventilation.
International guidelines currently recommend the use of the
same maintenance medication during the pandemic, including a
regular treatment with ICS in asthmatics8-10 or in patients with
COPD11 who are frequent exacerbators with forced expiratory
volume in 1 second (FEV1) lower than 50%. Corticosteroids are
immunosuppressive drugs and could be deleterious during viral
infection. Dong et al,12 however, previously confirmed the safety
of ICS use in patients with COPD.
In our study, we collected data from patients who were
hospitalized due to COVID19 and classified them according to
their lung status either in a nonobstructive group or in an asthma
or COPD group. The aim of the study was to determine if
patients with asthma or COPD are at risk of experiencing an
ICU admission and death as compared with nonobstructive
patients.METHODS
We collected data from the electronic medical record from 596
adult patients who were hospitalized in University Hospital of Liege
between March 18 and April 17, 2020, for COVID19.
Demographic characteristics, maintenance treatments, and
comorbidities at baseline were extracted. Subjects were characterized
as atopic if they had at least 1 positive specific IgE test (0.35 kU/L;
Phadia, Groot-Bijgaarden, Belgium) for at least 1 common
aeroallergen (cat, dog, house dust mites, grass pollen, tree pollen, and
a mixture of molds). Chronic renal failure was defined as a perma-
nent reduction in glomerular filtration rate <60 mL/min/1.73 m2.
Cardiopathy involved ischemic cardiomyopathy, hypertensive
cardiomyopathy, chronic heart failure, cardiomegaly, cardiac
hypertrophy, and congestive heart failure. Emphysema and bron-
chiectasis were defined based on chest computed tomography (CT)
according to current guidelines13,14 and according to lung function
testing for emphysema. Immunosuppressive diseases recorded
among hospitalized patients were grafts, history of splenectomy, and
HIV infection.
We classified patients into 3 groups according to the underlying
respiratory disease that was present before COVID19. The diagnosis
was done by a pulmonologist according to lung function tests,
bronchodilation test, and methacholine concentration provoking a
20% fall in FEV1 if necessary as previously described.
15,16 We
distinguished one group with asthmatics, a second group with
patients suffering from COPD, and a third group with all patients
without a history of obstructive pulmonary disease. The latest lung
function tests performed over the last 3 years were reported in
patients with asthma and COPD. Symptoms at admission such as
dyspnea, chest pain, rhinorrhea, pharyngeal pain, nonproductive and
productive cough, diarrhea, headache, myalgia, fever, nausea, and
vomiting were extracted. Ambient air oxygen saturation was
measured, blood sampling was taken at hospital admission, and chest
CT scan was performed.
We reported the number of cycles of polymerase chain reaction
(PCR) COVID19 (gene E and gene open reading frame 1ab
[ORF1ab]) at baseline. We used a real-time RT-PCR test intended
for the qualitative detection of nucleic acids from SARS-CoV2 in
TABLE I. Demographic, treatment, and functional characteristics and comorbidities of patients hospitalized for SARS-CoV2 infection
according to the presence or absence of asthma and COPD
No obstruction (N [ 493) Asthma (N [ 57) COPD (N [ 46)
P valueN Value N Value N Value
Female gender 493 249 (50%) 57 32 (56%) 46 21 (46%) .56
Age (y) 493 58  19 57 53  18 46 74  10 <.0001
BMI (kg/m2) 243 27.8  5.8 32 28.6  7.5 37 27.9  5.4 .80
Smoking status 411 57 46 <.0001
Nonsmoker 268 (65%) 41 (72%) 3 (7%)
Ex-smoker 102 (25%) 13 (23%) 37 (80%)
Smoker 41 (10%) 3 (5%) 6 (13%)
Anxiolytics 480 38 (8%) 56 2 (4%) 41 13 (32%) <.0001
Aspirin 480 96 (20%) 56 7 (12%) 41 20 (49%) <.0001
Azithromycin 485 0 (0%) 56 0 (0%) 42 3 (7%) <.0001
ICS 493 0 (0%) 57 40 (70%) 46 16 (35%) <.0001
Low dose 0 3 6
Moderate dose 0 17 7
High dose 0 20 3
OCS (dose, mg) 493 20 (4%) (16 mg) 57 2 (3%) (4 mg) 46 1 (2%) (4 mg) .81
Post-BD FEV1, % pred 0 e 57 88 (70-101) 46 64 (53-72) <.0001
Post-BD FEV1/FVC (%) 0 e 57 69 (63-87) 46 58 (52-68) .0062
FVC, % pred 0 e 57 89 (80-99) 46 80 (68-92) .041
TLC, % pred 0 e 30 95 (88-106) 22 100 (93-112) .41
RV/TLC, % pred 0 e 27 37 (27-45) 18 53 (49-58) .0002
FRC, % pred 0 e 28 105 (91-134) 15 121 (104-147) .27
RV, % pred 0 e 29 96 (80-125) 20 120 (97-150) .066
DLCO,% pred 0 e 30 80 (68-87) 25 47 (32-64) .0003
KCO, % pred 0 e 29 91 (76-102) 24 72 (56-91) .023
sGaw, % pred 0 e 19 60 (42-72) 7 40 (34-66) .15
Atopy 484 105 (22%) 56 35 (62%) 46 14 (30%) <.0001
Emphysema 350 35 (10%) 56 7 (15%) 46 28 (61%) <.0001
Bronchiectasis 493 15 (3%) 56 4 (7%) 46 4 (9%) .067
Cardiopathy 493 88 (18%) 56 8 (14%) 46 20 (43%) <.0001
Diabetes 493 90 (18%) 56 11 (20%) 46 13 (28%) .26
History of cancer 493 53 (11%) 56 3 (5%) 46 14 (30%) .0007
Immunosuppressive disease 493 28 (6%) 57 0 (0%) 46 4 (9%) .11
Hypertension 493 198 (40%) 56 19 (34%) 46 29 (63%) .0053
Dyslipidemia 493 109 (22%) 56 12 (21%) 46 16 (35%) .14
Obesity 493 89 (18%) 56 12 (21%) 46 14 (30%) .12
CRF 493 32 (7%) 56 2 (4%) 46 8 (17%) .012
GOR 479 65 (14%) 56 7 (12%) 41 16 (39%) <.0001
BD, Bronchodilation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; DLCO, diffusing capacity of the lungs for carbon
monoxide; FEV1, forced expiratory volume in 1 second; FRC, functional residual capacity; FVC, forced vital capacity; GOR, gastroesophageal reflux; ICS, inhaled cortico-
steroid; IQR, interquartile range; KCO, carbon monoxide transfer coefficient; OCS, oral corticosteroid; RV, residual volume; SARS-CoV2, severe acute respiratory syndrome
coronavirus 2; SD, standard deviation; sGaw, specific conductance; TLC, total lung capacity.
Values are n (%) and P value c2 test for contingency tables, or mean  SD and P value analysis of variance, or median (IQR) and P value Kruskal-Wallis test.
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use on the Cobas 6800/8800 systems). We detected specific nucleic
acid sequences from the nonstructural ORF1ab in the genome of the
SARS-CoV2 virus in the carboxyfluorescein channel and the
conserved sequences in the structural envelope (E) gene to provide a
high degree of robustness.
A “COVID working group” constituted in the University
Hospital of Liege at the beginning of the pandemic decided to treat
all hospitalized patients tested positive to COVID19 with hydrox-
ychloroquine for 5 days (400 mg on day 1 and 200 mg from day 2 today 5) and doxycycline 200 mg per day for 5 days, but this was not
part of a clinical trial.
Statistical analysis
The results were expressed as mean  standard deviation for
continuous variables; median (interquartile range) was preferred for
skewed distributions. For categorical variables, the number of
observations and percentages are given in each category. For
continuous variables, comparisons between different subgroups were
performed with the analysis of variance method or using Kruskal-
TABLE II. Percentage of patients reporting symptoms at admis-
sion when hospitalized for SARS-CoV2 infection according to the
presence or absence of asthma and COPD
No
obstruction Asthma COPD P value
N 245 30 9
Fever 163 (67%) 20 (67%) 6 (67%) .99
Headache 156 (64%) 21 (70%) 1 (11%) .0040
Nonproductive cough 150 (61%) 21 (70%) 4 (44%) .36
Myalgia 152 (62%) 17 (57%) 2 (22%) .052
Dyspnea 116 (47%) 15 (50%) 6 (67%) .51
Chest pain 78 (32%) 10 (33%) 2 (22%) .81
Diarrhea 74 (30%) 10 (33%) 2 (22%) .81
Nausea 74 (30%) 7 (23%) 0 (0%) .11
Rhinorrhea 54 (22%) 7 (23%) 0 (0%) .28
Pharyngeal pain 52 (21%) 6 (20%) 0 (0%) .30
Productive cough 50 (20%) 4 (13%) 3 (33%) .40
Vomiting 23 (9%) 1 (3%) 0 (0%) .35
COPD, Chronic obstructive pulmonary disease; SARS-CoV2, severe acute respira-
tory syndrome coronavirus 2.
Values are n (%) and P value c2 test for contingency tables.
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tables was used for categorical variables. Variables associated with
ICU admission and death were identified by binary logistic regres-
sion. For each variable, results were presented as odds ratios (OR),
their 95% confidence intervals (95% CI), and P values of simple
logistic regression models and logistic regression models adjusted for
age and gender. Multiple regression models were built for each
outcome (ICU stay and death) including age, gender, asthma,
COPD, and the other comorbidities with P < .10 in the models
adjusted for age and gender. Because atopy is highly correlated with
asthma, this variable was not included in the multiple model pre-
dicting ICU stay. Final multiple models obtained by stepwise se-
lection (with age, gender, asthma, and COPD forced to be included)
were presented in the results. In all the regression models, skewed
continuous variables were log-transformed or expressed as ordered
qualitative variables.
A P value <.05 was considered as statistically significant. Missing
values were not replaced. Statistical analysis was performed using
SAS (version 9.4) software (Cary, NC).
RESULTS
Demographic characteristics
Among the 596 patients requiring hospitalization for
COVID19, asthma and COPD accounted for 9.6% (N ¼ 57)
and 7.7% (N ¼ 46), respectively. Not surprisingly, asthmatic
patients were more often atopic than COPD and non-
obstructive ones (Table I). Patients with COPD were older,
more often current or ex-smokers with higher rates of
emphysema. Regarding comorbidities, patients with COPD had
more often hypertension, gastroesophageal reflux, cardiopathy,
chronic renal failure, and a cancer history. Patients with chronic
airway obstructive diseases were more often treated with anxi-
olytics before admission. Seventy percent of asthmatics were
treated with ICS, and half of them received high doses of ICS
(1000 mg of beclomethasone equivalent per day). One-third
of patients with COPD were treated with ICS with 19% of
them receiving high doses and 44% moderate doses of ICS.Three percent of patients with asthma and 2% of patients with
COPD received chronic oral corticosteroid (OCS) with a
median dose of 4 mg per day, whereas 4% of the nonobstructive
patients were treated with chronic OCS with a median dose of
16 mg per day.
Symptoms at admission and SARS-COV2 PCR
Fever, headache, nonproductive cough, and myalgia were the
most common symptoms at admission (Table II). Patients
with COPD had less headache than asthmatics and non-
obstructive patients. Other symptoms were similar between the
subgroups.
The numbers of cycles of positive PCR for COVID19 gene E
and gene ORF1ab were similar between the groups (Table III).
Risk factors for intensive care unit stay
The proportions of asthmatics (N ¼ 10 of 57), patients with
COPD (N ¼ 9 of 46), and patients without obstructive airway
disease (N ¼ 69 of 493) hospitalized in the ICU were 17.5%,
19.6%, and 14%, respectively (Table IV).
We searched for risk factors of being hospitalized in the ICU
for the whole population (Table V). The regression analysis
showed that male gender and older age increased the risk of ICU
stay. Independently from age and gender, atopy, obesity,
diabetes, high baseline C-reactive protein (CRP), D-dimers, and
fibrinogen levels were associated with a risk of ICU stay
(Table V). Moreover, higher white blood cell and neutrophil
counts, lower blood eosinophil and lymphocyte counts, lower
glomerular filtration rate, higher creatinine and urea levels, lower
concentration of albumin and higher procalcitonin, lactate
dehydrogenase (LDH) and creatinine kinase (CK) levels were
associated with a higher risk of ICU stay independently of age or
gender.
The multivariate analysis confirmed that male gender and
obesity were risk factors for hospitalization in the ICU (Table V).
Men had 1.9 times (95% CI: 1.1-3.2) more risk of ICU stay, and
obesity increased 8.5 times (95% CI: 5.1-14.1) the risk of ICU
stay. Interestingly, neither asthma or COPD nor ICS and OCS
treatments were significant risk factors for ICU admission.
Risk factors for death due to COVID19
One-third of patients with COPD hospitalized for SARS-
CoV2 infection died during hospitalization (34.8%, N ¼ 16
of 46), whereas only 7.0% of asthmatics (N ¼ 4 of 57) and
13.6% (N ¼ 67 of 493) of patients without obstructive airway
disease died due to COVID19 (Table IV). The regression
analysis revealed that male gender and older age increased the risk
of death and that, independently of age and gender, cardiopathy,
diabetes, immunosuppressive disease, obesity, and chronic renal
failure were predictors of death in hospitalized patients
(Table VI). Higher baseline CRP levels increased the risk of
death. The level of LDH was higher and the value of albumin
was lower at admission to the hospital in patients who died of
SARS-CoV2 infection. Patients dying of COVID19 had also a
significantly lower number of cycles of PCR gene E and
ORF1ab, suggesting a higher viral load (Figure 1). Moreover,
higher levels of white blood cells, neutrophils, urea, procalcito-
nin, and CK and lower levels of eosinophils, monocytes, red
blood cells, hemoglobin, and total proteins were predictors of
death.
The multivariate analysis confirmed that male gender, older
age, cardiopathy, and immunosuppressive disease were predictors
TABLE III. Blood tests and chest CTscan results at admission to the hospital
No obstruction (N [ 493) Asthma (N [ 57) COPD (N [ 46)
P valueN Median (IQR) N Median (IQR) N Median (IQR)
White blood cells (/mm3) 323 6370 (4650-8230) 31 6280 (5080-9830) 43 6080 (4620-9960) .83
Lymphocytes (/mm3) 322 890 (650-1250) 31 1060 (700-1370) 42 1000 (630-1280) .39
Neutrophils (/mm3) 322 4755 (3180-6580) 31 4520 (3200-7050) 42 4170 (2630-6670) .92
Eosinophils (/mm3) 322 10 (0-30) 31 10 (0-50) 42 10 (0-60) .42
Basophils (/mm3) 322 20 (10-30) 31 20 (10-30) 42 20 (10-30) .71
Monocytes (/mm3) 322 390 (250-560) 31 450 (300-630) 42 430 (240-820) .47
Platelets (/mm3) 323 197 (159-264) 30 194 (167-269) 43 179 (151-315) .92
Red blood cells (106/mm3) 318 4.6 (4.1-4.9) 30 4.8 (4.3-5.3) 40 4.2 (3.8-4.7) .026
Hemoglobin (g/dL) 323 13.5 (12.2-14.8) 30 14.0 (12.2-15.1) 43 12.6 (11.1-14.3) .078
GFR (mL/min/1.73 m2) 319 72 (51-90) 30 67 (49-89) 43 61 (46-82) .29
Creatinine (mg/dL) 320 0.95 (0.76-1.3) 30 1.0 (0.69-1.4) 43 1.0 (0.75-1.5) .56
Urea (mg/dL) 320 40 (29-59) 29 49 (27-64) 42 51 (32-74) .06
Albumin (g/L) 290 38 (35-41) 29 40 (37-42) 36 37 (33-41) .14
Total proteins (g/L) 300 69 (64-74) 30 70 (66-76) 37 67 (63-70) .12
Bicarbonates (mmol/L) 280 24 (22-26) 27 25 (22-26) 34 26 (22-29) .04
CRP (mg/L) 323 76 (28-152) 31 60 (10-117) 43 55 (15-111) .11
D-dimers (mg/L) 249 826 (486-1644) 24 582 (460-1140) 28 947 (494-1996) .29
Fibrinogen (g/L) 290 5.1 (4.2-6.5) 25 4.9 (4.4-6.0) 33 4.3 (3.8-5.5) .018
Procalcitonin (mg/L) 250 0.10 (0.05-0.24) 25 0.08 (0.02-0.45) 27 0.07 (0.04-0.40) .90
LDH (U/L) 299 332 (250-446) 29 356 (266-503) 35 279 (216-383) .10
CK (UI/L) 292 134 (67-298) 27 115 (63-323) 32 106 (55-553) .88
PCR COVID gene E positif 493 493 (100%) 57 56 (98.2%) 46 45 (97.8%)
No. of cycles 241 27 (22-32) 31 29 (21-33) 25 24 (22-31) .71
PCR COVID ORF1ab positif 493 493 (100%) 57 56 (98.2%) 46 45 (97.8%)
No. of cycles 240 27 (21-31) 31 28 (21-31) 25 24 (22-30) .77
CK, Creatinine kinase; COPD, chronic obstructive pulmonary disease; COVID, coronavirus disease; CRP, C reactive protein; CT, computed tomography; GFR, glomerular
filtration rate; IQR, interquartile range; LDH, lactate dehydrogenase; ORF, open reading frame; PCR, polymerase chain reaction.
Number of cycles <19: very high positive, 19-25: high positive, 26-33: moderate positive, >33: low positive.
Values are median (IQR) and P values of the Kruskal-Wallis test, or n (%).
TABLE IV. Deterioration and death rate of patients hospitalized
for SARS-CoV2 infection according to the presence or absence of
asthma and COPD
No obstruction Asthma COPD
N 493 57 46
ICU, n (%) 69 (14.0) 10 (17.5) 9 (19.6)
Mechanical ventilation
days (range)
12 (10-18) 12 (9-23) 17 (9-24)
Death, n (%) 67 (13.6) 4 (7.0) 16 (34.8)
COPD, Chronic obstructive pulmonary disease; ICU, intensive care unit; SARS-
CoV2, severe acute respiratory syndrome coronavirus 2.
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COPD was a predictor of death in the univariate but not in the
age- and gender-adjusted models nor in the multivariate analysis,
suggesting that this risk is probably linked to the higher rate of
comorbidities recorded in this subpopulation and to the older age
of this subgroup. As for ICU admission, neither asthma nor
ICS and OCS treatments were significant risk factors for
mortality.
DISCUSSION
ICU stay was necessary in one-fifth of asthmatics and patients
with COPD hospitalized due to SARS-CoV2 infection.Predictors of hospitalization in the ICU were gender and obesity.
The presence of high baseline CRP levels increased the risk of
ICU admission. Asthma, COPD, ICS treatment, and chronic
OCS requirement were not identified as significant risk factors
for ICU admission or mortality. The multivariate analysis
showed that male gender, older age, cardiopathy, and immu-
nosuppressive disease were independent predictors of death in
patients hospitalized for SARS-CoV2 infection.
In the previous reports on COVID19, the prevalence of
asthma in patients with SARS-CoV2 infection was surprisingly
low.3,17 However, most of the first reports combined asthmatics
and patients with COPD in a “chronic obstructive respiratory
diseases” group, and it has been suggested that chronic pulmo-
nary diseases were underdiagnosed in the first studies.18 The
proportion of asthmatics and patients with COPD hospitalized
in the CHU of Liege due to COVID19 is similar to the one
reported by Richardson et al19 and close to the percentage of
patients suffering from these diseases in the general popula-
tion.20,21 This suggests that asthma and COPD are not risk
factors for hospitalization due to SARS-CoV2 infection. One
hypothesis is that asthmatics and patients with COPD were more
compliant to their treatment22 and respected social distancing
during the pandemic because they were afraid of having severe
pulmonary infection. A protective role of inhalation therapy by
ICS has also been proposed as a possible explanation. Moreover,
Peters et al4 found that there were no significant differences in
TABLE V. Factors associated with intensive care unit stay due to SARS-CoV2 infection: results of the logistic regression analysis
Simple logistic regression




model (N [ 595)
N OR (95% CI) P value N OR (95% CI) P value OR (95% CI) P value
Male gender 596 2.0 (1.2-0.3.2) .0041 e e e 1.9 (1.1-3.2) .013
Age (by 10 y) 596 1.2 (1.04-1.3) .0093 e e e 1.1 (0.96-1.3) .17
BMI (kg/m2) 312 1.1 (1.1-1.2) <.0001 312 1.1 (1.1-1.2) <.0001 e e
Smoker or ex-smoker 514 1.8 (1.1-2.9) .017 514 1.5 (0.90-2.5) .12 e e
Atopy 586 2.1 (1.3-3.4) .0021 586 2.4 (1.5-3.9) .0005 e e
Emphysema 452 0.72 (0.36-1.4) .34 452 0.66 (0.32-1.3) .24 e e
Bronchiectasis 595 0.86 (0.25-3.0) .81 595 0.61 (0.17-2.1) .44 e e
Cardiopathy 595 1.3 (0.73-2.2) .41 595 0.94 (0.53-1.7) .84 e e
Diabetes 595 2.3 (1.4-3.8) .0013 595 2.1 (1.2-3.5) .0060 e e
History of cancer 595 1.7 (0.91-3.1) .099 595 1.3 (0.69-2.5) .40 e e
Immunosuppressive disease 596 0.82 (0.28-2.4) .71 596 0.73 (0.25-2.1) .57 e e
Hypertension 595 1.9 (1.2-3.0) .0070 595 1.3 (0.98-2.7) .061 e e
Dyslipidemia 595 1.9 (1.2-3.2) .0083 595 1.6 (0.92-2.6) .10 e e
Obesity 595 9.0 (4.5-15) <.0001 595 8.5 (5.1-14) <.0001 8.5 (5.1-14.1) <.0001
CRF 595 0.96 (0.39-2.3) .92 595 0.82 (0.33-2.0) .68 e e
GOR 576 1.9 (1.04-3.4) .036 576 1.6 (0.85-2.9) .15 e e
Asthma 596 1.3 (0.61-2.6) .53 596 1.4 (0.69-3.0) .33 1.4 (0.64-3.2) .39
COPD 596 1.4 (0.67-3.1) .34 596 1.1 (0.52-2.5) .74 0.94 (0.39-2.2) .89
Anxiolytics 577 1.4 (0.64-2.9) .41 577 1.1 (0.48-2.4) .86
Aspirin 577 2.4 (1.5-4.1) .0007 577 1.9 (1.1-3.5) .030
Azithromycin 583 13 (1.2-150) .035 583 13 (1.1-152) .041
ICS 596 1.9 (0.91-3.8) .088 596 1.8 (0.85-3.7) .13
OCS 596 2.1 (0.81-5.5) .13 596 2.1 (0.80-5.6) .13
Blood test at admission
White blood cells (/mm3)* 397 2.9 (1.7-4.8) <.0001 397 2.9 (1.7-4.8) <.0001
Lymphocytes (/mm3)* 395 0.64 (0.41-0.99) .047 395 0.60 (0.38-0.96) .031
Neutrophils (/mm3)* 395 2.9 (1.8-4.5) <.0001 395 2.9 (1.9-4.6) <.0001
Eosinophils (/mm3)* 395 0.91 (0.87-0.96) .0001 395 0.91 (0.87-0.96) .0002
Basophils (/mm3)* 395 0.99 (0.92-1.1) .70 395 0.99 (0.92-1.1) .77
Monocytes (/mm3)* 395 1.02 (0.87-1.2) .83 395 1.02 (0.87-1.2) .80
Platelets (/mm3)* 396 0.77 (0.46-1.3) .31 396 0.78 (0.46-1.3) .34
Red blood cells (106/mm3) 388 1.4 (0.997-2.0) .052 388 1.3 (0.91-1.8) .46
Hemoglobin (g/dL) 396 1.1 (1.02-1.3) .024 396 1.1 (0.99-1.3) .086
GFR (mL/min/1.73 m2) 392 0.99 (0.98-0.99) .0057 392 0.98 (0.97-0.99) .0001
Creatinine (mg/dL)* 393 1.9 (1.2-3.1) .011 393 2.1 (1.3-3.6) .0042
Urea (mg/dL)* 391 1.9 (1.2-2.9) .0027 391 2.7 (1.7-4.3) <.0001
Albumin (g/L) 355 0.92 (0.88-0.97) .0022 355 0.90 (0.86-0.95) .0002
Total proteins (g/L) 367 0.98 (0.95-1.01) .15 367 0.97 (0.94-1.001) .057
Bicarbonates (mmol/L) 341 0.97 (0.91-1.04) .34 341 0.97 (0.91-1.04) .39
CRP (mg/L)† 397 2.1 (1.7-2.8) <.0001 397 2.2 (1.7-2.9) <.0001
D-dimers (mg/L)* 301 1.6 (1.2-2.0) .0009 301 1.7 (1.3-2.3) .0002
Fibrinogen (g/L) 348 1.5 (1.3-1.7) <.0001 348 1.4 (1.2-1.7) <.0001
Procalcitonin (mg/L)* 302 1.6 (1.3-1.9) <.0001 302 1.8 (1.4-2.2) <.0001
LDH (U/L)* 363 15 (7.4-30) <.0001 363 17 (8.1-34) <.0001
CK (UI/L)* 351 1.5 (1.2-1.9) .0003 351 1.5 (1.2-1.9) .0003
BMI, Body mass index; CI, confidence interval; CK, creatinine kinase; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; CRP, C-reactive protein;
GFR, glomerular filtration rate; GOR, gastroesophageal reflux; ICS, inhaled corticosteroid; LDH, lactate dehydrogenase; OCS, oral corticosteroid; OR, odds ratio; SARS-CoV2,
severe acute respiratory syndrome coronavirus 2.
Bold P-values are considered as significant.
*Log-transformed.
†CRP: 0 if 25.6, 1 if >25.6 and 71.6, 2 if >71.6 and 148.7, and 3 if >148.7 and 500.
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for age and gender
Multiple logistic regression
final model (N [ 595)
N OR (95% CI) P value N OR (95% CI) P value OR (95% CI) P value
Male gender 596 2.2 (1.4-3.5) .0013 e e e 1.9 (1.1-3.2) .016
Age (by 10 y) 596 1.9 (1.6-2.3) <.0001 e e e 1.9 (1.6-2.3) <.0001
BMI (kg/m2) 312 1.0 (0.96-1.05) .98 312 1.0 (0.97-1.1) .47 e e
Smoker or ex-smoker 514 2.3 (1.4-3.7) .0008 514 1.4 (0.81-2.3) .24 e e
Atopy 586 1.03 (0.61-1.7) .91 586 1.2 (0.68-2.1) .53 e e
Emphysema 452 1.7 (0.96-3.1) .068 452 1.3 (0.68-2.3) .46 e e
Bronchiectasis 595 4.1 (1.47-9.7) .0016 595 1.9 (0.73-4.7) .20 e e
Cardiopathy 595 3.6 (2.2-5.8) <.0001 595 1.9 (1.1-3.2) .018 1.8 (1.05-3.1) .033
Diabetes 595 2.3 (1.4-3.9) .0011 595 1.8 (1.1-3.1) .031 e e
History of cancer 595 3.2 (1.8-5.7) <.0001 595 1.7 (0.94-3.2) .078 e e
Immunosuppressive disease 596 3.4 (1.6-7.2) .0020 596 3.8 (1.6-8.6) .0017 3.6 (1.5-8.4) .0031
Hypertension 595 2.9 (1.8-4.6) <.0001 595 1.4 (0.80-2.3) .25 e e
Dyslipidemia 595 2.9 (1.8-4.6) <.0001 595 1.4 (0.86-2.4) .17 e e
Obesity 595 2.0 (1.2-3.3) .0078 595 1.8 (1.1-3.2) .029 e e
CRF 595 3.7 (1.9-7.3) .0002 595 2.5 (1.2-5.3) .014 e e
GOR 576 1.8 (1.004-3.2) .048 576 0.86 (0.45-1.7) .66 e e
Asthma 596 0.41 (0.15-1.2) .098 596 0.59 (0.20-1.8) .35 0.74 (0.24-2.3) .59
COPD 596 3.6 (1.9-6.9) <.0001 596 1.9 (0.95-3.8) .071 1.6 (0.80-3.3) .18
Anxiolytics 577 2.8 (1.4-5.3) .0020 577 1.1 (0.56-2.4) .70
Aspirin 577 3.2 (1.9-5.2) <.0001 577 0.97 (0.54-1.7) .93
Azithromycin 583 e e 583 e e
ICS 596 1.7 (0.79-3.4) .18 596 1.4 (0.62-3.0) .44
OCS 596 2.1 (0.82-5.6) .12 596 2.5 (0.88-7.2) .085
Blood test at admission
White blood cells (/mm3)* 397 2.1 (1.3-3.4) .0041 397 2.1 (1.2-3.5) .0062
Lymphocytes (/mm3)* 395 0.60 (0.38-0.94) .027 395 0.74 (0.47-1.2) .20
Neutrophils (/mm3)* 395 2.1 (1.4-3.3) .0006 395 2.1 (1.3-3.4) .0013
Eosinophils (/mm3)* 395 0.95 (0.91-0.99) .028 395 0.94 (0.90-0.99) .024
Basophils (/mm3)* 395 0.94 (0.88-1.003) .060 395 0.94 (0.88-1.004) .067
Monocytes (/mm3)* 395 0.78 (0.65-0.93) .0060 395 0.74 (0.60-0.90) .0034
Platelets (/mm3)* 396 0.65 (0.39-1.1) .11 396 0.78 (0.45-1.3) .37
Red blood cells (106/mm3) 388 0.49 (0.35-0.68) <.0001 388 0.48 (0.34-0.70) .0001
Hemoglobin (g/dL) 396 0.82 (0.73-0.92) .0008 396 0.81 (0.72-0.92) .0009
GFR (mL/min/1.73 m2) 392 0.99 (0.98-1.000) .039 392 1.0 (0.99-1.008) .83
Creatinine (mg/dL)* 393 1.8 (1.1-3.0) .017 393 1.3 (0.75-2.3) .34
Urea (mg/dL)* 391 3.1 (2.0-4.9) <.0001 391 2.2 (1.3-3.6) .0026
Albumin (g/L) 355 0.84 (0.79-0.89) <.0001 355 0.85 (0.80-0.90) <.0001
Total proteins (g/L) 367 0.94 (0.91-0.97) <.0001 367 0.95 (0.92-0.98) .0018
Bicarbonates (mmol/L) 341 0.95 (0.88-1.01) .12 341 0.95 (0.89-1.02) .19
CRP (mg/L)† 397 1.9 (1.5-2.4) <.0001 397 1.9 (1.4-2.4) <.0001
D-dimers (mg/L)* 301 1.6 (1.2-2.1) .0012 301 1.3 (0.97-1.8) .072
Fibrinogen (g/L) 348 1.1 (0.92-1.3) .36 348 1.1 (0.94-1.3) .22
Procalcitonin (mg/L)* 302 1.7 (1.3-2.0) <.0001 302 1.5 (1.2-1.9) .0002
LDH (U/L)* 363 3.0 (1.7-5.2) <.0001 363 3.1 (1.7-5.6) .0002
CK (UI/L)* 351 1.4 (1.1-1.7) .0040 351 1.3 (1.02-1.7) .032
BMI, Body mass index; CI, confidence interval; CK, creatinine kinase; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; CRP, C-reactive protein;
GFR, glomerular filtration rate; GOR, gastroesophageal reflux; ICS, inhaled corticosteroid; LDH, lactate dehydrogenase; OCS, oral corticosteroid; OR, odds ratio; SARS-CoV2,
severe acute respiratory syndrome coronavirus 2.
Bold P-values are considered as significant.
*Log-transformed.
†CRP: 0 if 25.6, 1 if >25.6 and 71.6, 2 if >71.6 and 148.7, and 3 if >148.7 and 500.
J ALLERGY CLIN IMMUNOL PRACT
VOLUME -, NUMBER -
CALMES ETAL 7
FIGURE 1. Comparison of clinical parameters in patients who died during SARS-CoV2 infection as compared with patients who survived.
COVID19, Coronavirus disease 2019; CRP, C-reactive protein; LDH, lactate dehydrogenase; ORF, open reading frame; PCR, polymerase
chain reaction.
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sputum between patients with asthma and healthy subjects,
suggesting that patients with asthma might not be at increased
risk of COVID19. However, we have to recognize that
hospitalized asthmatics in our series are not representative of the
general population of asthmatics seen in our hospital15 because
the mean post-bronchodilation FEV1/forced vital capacity ratio
was below 70%, thereby indicating fixed airway obstruction. It
would therefore suggest that fixed airway obstruction in asthma
may be a risk factor to be hospitalized. However, among the 226
severe asthmatics treated with anti-IgE, anti-IL5, and anti-IL5R
in the Asthma Clinic of the CHU of Liege, only 4 presented a
SARS-CoV2 infection and none of them were admitted to the
hospital due to COVID19 (unpublished data).
We found that one-fifth of asthmatics and patients with
COPD who were hospitalized due to COVID19 required a stay
in the ICU. Previous studies have suggested that patients
suffering from airway obstructive disease had a deficient and
delayed innate antiviral immune response.1,2 In a meta-analysis,
Lippi and Henry23 reported that COPD was associated withsevere coronavirus disease with an OR of 5.69. In another study,
the prevalence of COPD was higher in the nonsurvivors.24 This
paper has however been retracted. In our population, COPD was
a predictor of death during hospitalization in the univariate but
not in the multivariate analysis, suggesting that this risk is
probably linked to the higher rate of comorbidities recorded in
this subpopulation and to the older age of this subgroup. Car-
diopathy is indeed frequently associated with COPD and has
emerged as a key comorbidity to predict death after COVID19.
In our study, we confirm that older age and high number of
comorbidities are associated with more severe infections.3 Male
gender and the presence of obesity were indeed predictors of ICU
stay, whereas male gender, older age, cardiopathy, and
immunosuppressive disease were associated with death during
hospitalization. Male gender and a history of diabetes mellitus
have been found to be associated with an elevated ACE2, a
receptor for SARS-CoV2 to enter host target cells.4 In the report
of Li et al,17 patients with older age and hypertension were
significantly associated with severe COVID19 on admission.
Mehra et al25 found that underlying cardiovascular disease was
J ALLERGY CLIN IMMUNOL PRACT
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CALMES ETAL 9associated with increased risk of in-hospital death among patients
hospitalized with COVID19. We also found that high baseline
CRP levels at hospital admission were predictors of ICU stay or
death. We found higher fibrinogen and D-dimers levels in
patients who stayed in the ICU. This is not surprising as a high
incidence of thromboembolic events has been reported in such
patients, and this suggests an important role of SARS-Cov2-
induced endothelial activation.26
We did not find a higher risk of severe infections in patients
treated with ICS or OCS. It has been previously shown that type
2 inflammation may suppress antiviral immunity in the lung5
and may increase susceptibility to severe COVID19. Our
group also previously found that allergic asthma was character-
ized by impaired spontaneous release of IFN-gamma that
correlated with the magnitude of eosinophilic inflammation.27
Suppressing type 2 inflammation using local corticosteroids
may thus restore antiviral immunity. Moreover, it has been
recently suggested that ICS is dose-dependently associated with
reduced ACE2 mRNA expression. This observation was, how-
ever, not confirmed in a study looking at bronchial brushes.28
This suggests that patients with obstructive airway disease
should not decrease the dose of ICS during SARS-CoV2 infec-
tion as recommended by most of the current international
guidelines.8-10 Asthma and COPD treatments should be pursued
and adapted to ensure optimal control of the lung disease
throughout the epidemic, thus potentially reducing the risk of
severe COVID19 disease.
We also looked at intubation length according to airway status
and did not find that asthma prolonged intubation as compared
with nonobstructive patients. However, we found similar
intubation length to the one reported by Mahdavinia et al29 and
a prolonged intubation in patients with COPD.
Data related to smoking and risk of SARS-CoV2 infection
have been somewhat contradictory despite the fact that the as-
sociation between smoking and an increased risk of respiratory
diseases is clear. Recent publications suggested that smoking
upregulates the ACE2 receptor, which could increase the sus-
ceptibility to the infection.30 The proportion of current smokers
in our patients hospitalized for COVID19 was lower than that in
the general population in Belgium. In addition, smoking was not
a risk factor for ICU stay or death in our study. It might be that
smoking is protective against COVID19 by damaging cells that
are entrance gate to the virus such as pneumocytes type 2
expressing ACE2.CONCLUSION
Asthma and COPD are not risk factors for ICU stay and death
due to SARS-CoV2 infection. Independent predictors of hospi-
talization in the ICU were male gender and obesity. Male gender,
older age, cardiopathy, and immunosuppressive disease were
independent predictors of death due to COVID19.
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